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### Associations Between Cardiovascular Risk, Structural Brain Changes, and Cognitive Decline ![](fx1_lrg.gif) {#sec1.1.1}
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In a community-based, long-term, prospective cohort study with an imbedded neuroimaging study, the authors observed that higher Framingham General Cardiovascular Risk Score may predict decline in episodic memory, working memory, and perceptual speed. Furthermore, the authors found that higher Framingham General Cardiovascular Risk Score is associated with smaller hippocampal and gray matter volumes but greater white matter hyperintensities. These findings highlight the need to monitor and control cardiovascular risk burden to maintain healthy cognitive aging. This study provides the evidence that cardiovascular risk factors play an important role in neurodegeneration and vascular changes in the brain.
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### Physiological Stratification of Patients With Angina Due to Coronary Microvascular Dysfunction ![](fx1_lrg.gif) {#sec1.3.1}

[2538](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)34743-4){#intref0020}

Haseeb Rahman, Ozan M. Demir, Faisal Khan, Matthew Ryan, Howard Ellis, Mark T. Mills, Amedeo Chiribiri, Andrew Webb, Divaka Perera

Coronary microvascular dysfunction (CMD) is a heterogeneous disorder associated with poorer clinical outcomes that currently lacks disease-modifying therapies. Measurement of microvascular resistance during rest and pharmacological hyperemia can be easily performed in catheter laboratories and has identified 2 endotypes with disparate pathophysiological abnormalities. More than one-half of patients with CMD have abnormal resting flow related to nitric oxide dysregulation, which represents a novel therapeutic target. The other group has diminished peak flow and endothelial dysfunction and may therefore benefit more from traditional vasodilator therapy. This study provides the first description of the pathophysiological basis of these endotypes, which could potentially be translated to stratified management of this common condition.

Editorial Comment {#sec1.4}
-----------------

### Invasive Functional Assessment in Patients With Angina and Coronary Microvascular Dysfunction: A Plea for More {#sec1.4.1}

[2550](http://linkinghub.elsevier.com/retrieve/pii/S0735-1097(20)34744-6){#intref0025}

Carl J. Pepine, Islam Y. Elgendy

 {#sec1.5}

### Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects ![](fx1_lrg.gif) {#sec1.5.1}
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In this systematic review and meta-analyses, Embase, PubMed, and Web of Science searches until June 3, 2019, for peer-reviewed papers and conference abstracts reporting heterozygous familial hypercholesterolemia (FH) prevalence in nonfounder populations revealed 104 studies, including \>11 million subjects, eligible for inclusion. Compared with 1:313 among subjects in the general population, FH prevalence is 10-fold higher among subjects with ischemic heart disease (IHD), 20-fold higher among those with premature IHD, and 23-fold higher among those with severe hypercholesterolemia. Given the greater prevalence of FH in subjects with IHD and those with severe hypercholesterolemia, this study provides information worth taking into consideration when determining eligible populations in screening strategies.
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### Evolocumab in HIV-Infected Patients With Dyslipidemia: Primary Results of the Randomized, Double-Blind BEIJERINCK Study ![](fx1_lrg.gif) {#sec1.7.1}
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BEIJERINCK (Evolocumab Effect on LDL-C Lowering in Subjects with Human Immunodeficiency Virus and Increased Cardiovascular Risk) is the first randomized, double-blind, multinational trial comparing monthly subcutaneous evolocumab 420 mg with placebo in people living with human immunodeficiency virus (PLHIV). Treatment with evolocumab reduced low-density lipoprotein cholesterol (LDL-C) by 56.9% (95% confidence interval: 61.6% to 52.3%) from baseline to week 24 versus placebo; evolocumab also reduced the concentration of other atherogenic lipids, including non--high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) (all p \< 0.0001). Evolocumab was well tolerated in PLHIV and the patient incidence of treatment-emergent adverse events was similar between evolocumab and placebo groups. Evolocumab is effective in reducing LDL-C and other atherogenic lipoproteins in PLHIV with high cardiovascular risk not benefiting from maximally-tolerated statin therapy.
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### Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction ![](fx1_lrg.gif) {#sec1.9.1}
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Oral P2Y~12~ receptor antagonists exhibit delayed onset of platelet inhibition in patients with acute myocardial infarction (AMI). Selatogrel is a potent, highly selective, and reversible P2Y~12~ receptor antagonist with a rapid onset and offset of action. In 47 patients with AMI, single-dose subcutaneous administration of selatogrel (8 or 16 mg) induced a rapid inhibition of platelet aggregation response within 15 min (peak effect at 60 and 30 min post-dose, respectively) and was well tolerated with no major bleeding events. These data support further studies to explore the clinical benefit and safety of very early and pronounced platelet inhibition in patients with AMI.
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### Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: *JACC* State-of-the-Art Review ![](fx1_lrg.gif) {#sec2.1.1}
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Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. Since the last publication of prevention guideline specific to women in 2011, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, atrial fibrillation and primary prevention guidelines. The American College of Cardiology CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations in regard to risk factor and treatment pertinent to women.
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